Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sevicontrol-1: Efficacy and safety of a fixed combination of olmesartan 40 mg / amlodipine 10 mg in patients with insufficiently controlled hypertension under monotherapy with candesartan 32 mg - an open phase IIIb trial.[SEVICONTROL-1:Wirksamkeit und Sicherheit einer Fixkombination Olmesartan 40 mg / Amlodipin 10 mg bei Patienten mit einer unter Candesartan 32 mg Monotherapie unzureichend kontrollierter moderater essentieller Hypertonie – eine offene Phase IIIb – Studie]

Next Previous
Trial Profile

Sevicontrol-1: Efficacy and safety of a fixed combination of olmesartan 40 mg / amlodipine 10 mg in patients with insufficiently controlled hypertension under monotherapy with candesartan 32 mg - an open phase IIIb trial.[SEVICONTROL-1:Wirksamkeit und Sicherheit einer Fixkombination Olmesartan 40 mg / Amlodipin 10 mg bei Patienten mit einer unter Candesartan 32 mg Monotherapie unzureichend kontrollierter moderater essentieller Hypertonie – eine offene Phase IIIb – Studie]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Candesartan cilexetil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms Sevicontrol-1

    • Most Recent Events

    • 25 Sep 2012 Status changed from active, no longer recruiting to completed as reported by German Clinical Trials Register.
    • 01 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register.
    • 27 Jul 2012 Drug company (Daiichi Sankyo) added as reported by European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top